BR112012017994B8 - composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio - Google Patents
composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbioInfo
- Publication number
- BR112012017994B8 BR112012017994B8 BR112012017994A BR112012017994A BR112012017994B8 BR 112012017994 B8 BR112012017994 B8 BR 112012017994B8 BR 112012017994 A BR112012017994 A BR 112012017994A BR 112012017994 A BR112012017994 A BR 112012017994A BR 112012017994 B8 BR112012017994 B8 BR 112012017994B8
- Authority
- BR
- Brazil
- Prior art keywords
- liquid composition
- disorder
- treating
- preparing
- methods
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29696410P | 2010-01-21 | 2010-01-21 | |
| EP10151326 | 2010-01-21 | ||
| PCT/EP2011/050854 WO2011089234A2 (en) | 2010-01-21 | 2011-01-21 | Method and composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012017994A2 BR112012017994A2 (pt) | 2016-05-03 |
| BR112012017994B1 BR112012017994B1 (pt) | 2020-01-14 |
| BR112012017994B8 true BR112012017994B8 (pt) | 2020-12-08 |
Family
ID=42212171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012017994A BR112012017994B8 (pt) | 2010-01-21 | 2011-01-21 | composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9061016B2 (enExample) |
| EP (1) | EP2525796B1 (enExample) |
| JP (2) | JP5845193B2 (enExample) |
| KR (1) | KR101727085B1 (enExample) |
| CN (2) | CN102781447B (enExample) |
| AU (1) | AU2011208681B2 (enExample) |
| BR (1) | BR112012017994B8 (enExample) |
| CA (1) | CA2786824C (enExample) |
| CY (1) | CY1117659T1 (enExample) |
| DK (1) | DK2525796T3 (enExample) |
| ES (1) | ES2578513T3 (enExample) |
| HU (1) | HUE028285T2 (enExample) |
| IL (1) | IL220318A (enExample) |
| IN (1) | IN2012DN05192A (enExample) |
| PH (1) | PH12012501402A1 (enExample) |
| PL (1) | PL2525796T3 (enExample) |
| PT (1) | PT2525796T (enExample) |
| RU (1) | RU2571566C2 (enExample) |
| SG (1) | SG182537A1 (enExample) |
| SM (1) | SMT201600189B (enExample) |
| WO (1) | WO2011089234A2 (enExample) |
| ZA (1) | ZA201204424B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011089234A2 (en) * | 2010-01-21 | 2011-07-28 | Aprea Ab | Method and composition |
| CN104860994A (zh) * | 2014-02-20 | 2015-08-26 | 中国药科大学 | 3-奎宁环酮类含磷化合物的制备及其医药用途 |
| CN109280056A (zh) * | 2017-07-21 | 2019-01-29 | 上海时莱生物技术有限公司 | 手性3-奎宁环酮类化合物、制备方法及用途 |
| EP3762035A4 (en) * | 2018-03-09 | 2022-03-02 | Texas Tech University System | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF ALT CANCER |
| US20220087987A1 (en) * | 2018-12-27 | 2022-03-24 | National Cancer Center | A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor |
| WO2021053155A1 (en) | 2019-09-18 | 2021-03-25 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein |
| US20230089530A1 (en) * | 2020-02-09 | 2023-03-23 | Newave Pharmaceutical Inc. | Quinuclidinone analogues as anticancer agents |
| CN111257458B (zh) * | 2020-02-20 | 2022-07-22 | 北京鑫开元医药科技有限公司海南分公司 | 一种3-奎宁环酮盐酸盐的检测方法及应用 |
| WO2021170772A1 (en) | 2020-02-26 | 2021-09-02 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling |
| WO2021180338A1 (en) | 2020-03-09 | 2021-09-16 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3775418A (en) * | 1970-07-15 | 1973-11-27 | American Home Prod | 3-((3-azaspiro(5,5)undecino)methyl)-3-quinuclidinol |
| CA2423192C (en) | 2000-09-20 | 2010-11-23 | Karolinska Innovations Ab | 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| RU2226288C2 (ru) | 2001-07-10 | 2004-03-27 | ОПТИВА, Инк. | Многослойное оптическое покрытие |
| DE60306896T2 (de) | 2002-02-21 | 2007-02-15 | Aprea Ab | Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen |
| EP1605939B1 (en) | 2003-03-24 | 2008-10-15 | Aprea Ab | Pharmaceutical use of 1-azabicyclo¬ 2.2.2 octanes and a method of testing compounds for the ability of activating inactive wt p53 |
| SE0400708D0 (sv) * | 2004-03-22 | 2004-03-22 | Aprea Ab | New compounds and use thereof |
| JP2007269786A (ja) | 2006-03-09 | 2007-10-18 | Daiichi Sankyo Healthcare Co Ltd | パンテチン含有経口液剤 |
| JP2008001606A (ja) | 2006-06-20 | 2008-01-10 | Mitsubishi Pharma Corp | ピラゾロン化合物を含有する水溶液剤 |
| RU2419421C2 (ru) | 2006-07-18 | 2011-05-27 | Хенфарма Лабораторио С.Л. | Инъецируемая жидкая композиция парацетамола |
| JP2008201778A (ja) * | 2007-01-25 | 2008-09-04 | Mochida Pharmaceut Co Ltd | バンコマイシン液状製剤 |
| ES2384906T3 (es) | 2007-03-01 | 2012-07-13 | Novartis Ag | Mesilato de etilamida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, hidratos y polimorfos del mismo y formulaciones que comprenden estas formas |
| WO2011089234A2 (en) * | 2010-01-21 | 2011-07-28 | Aprea Ab | Method and composition |
-
2011
- 2011-01-21 WO PCT/EP2011/050854 patent/WO2011089234A2/en not_active Ceased
- 2011-01-21 BR BR112012017994A patent/BR112012017994B8/pt active IP Right Grant
- 2011-01-21 RU RU2012135698/15A patent/RU2571566C2/ru active
- 2011-01-21 HU HUE11701392A patent/HUE028285T2/en unknown
- 2011-01-21 EP EP11701392.0A patent/EP2525796B1/en active Active
- 2011-01-21 SG SG2012052221A patent/SG182537A1/en unknown
- 2011-01-21 DK DK11701392.0T patent/DK2525796T3/en active
- 2011-01-21 JP JP2012549372A patent/JP5845193B2/ja active Active
- 2011-01-21 US US13/521,841 patent/US9061016B2/en active Active
- 2011-01-21 CN CN201180006745.3A patent/CN102781447B/zh active Active
- 2011-01-21 PT PT117013920T patent/PT2525796T/pt unknown
- 2011-01-21 KR KR1020127021595A patent/KR101727085B1/ko active Active
- 2011-01-21 CN CN201610993086.1A patent/CN106963759B/zh active Active
- 2011-01-21 AU AU2011208681A patent/AU2011208681B2/en active Active
- 2011-01-21 PL PL11701392.0T patent/PL2525796T3/pl unknown
- 2011-01-21 IN IN5192DEN2012 patent/IN2012DN05192A/en unknown
- 2011-01-21 CA CA2786824A patent/CA2786824C/en active Active
- 2011-01-21 PH PH1/2012/501402A patent/PH12012501402A1/en unknown
- 2011-01-21 ES ES11701392.0T patent/ES2578513T3/es active Active
-
2012
- 2012-06-12 IL IL220318A patent/IL220318A/en active IP Right Grant
- 2012-06-15 ZA ZA2012/04424A patent/ZA201204424B/en unknown
-
2015
- 2015-08-05 JP JP2015154860A patent/JP6106228B2/ja active Active
-
2016
- 2016-06-17 CY CY20161100546T patent/CY1117659T1/el unknown
- 2016-06-20 SM SM201600189T patent/SMT201600189B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012017994A2 (pt) | composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio | |
| EA201290078A1 (ru) | Гетероциклические соединения для ингибирования pask | |
| EA201301154A1 (ru) | Разветвленные производные 3-фенилпропионовой кислоты и их применение | |
| EA201200318A1 (ru) | Гетероциклические оксимы | |
| BR112014026703A2 (pt) | inibidores de dna-pk | |
| EA200901488A1 (ru) | Замещенные имидазолопиридазины, как ингибиторы липидкиназы | |
| EA201391674A1 (ru) | Новые соединения, связывающие фарнезоидный x-рецептор (nr1h4) и модулирующие его активность | |
| EA200970931A1 (ru) | Аналоги гетероариламидов | |
| DK2150530T3 (da) | Substituerede sulfonamid-derivater | |
| UA107652C2 (en) | Carbazole compounds and therapeutic uses of the compounds | |
| EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| EA201390579A1 (ru) | Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы | |
| EA201390826A1 (ru) | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA | |
| EA201200918A1 (ru) | Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений | |
| GEP20196969B (en) | New therapeutical composition containing apomorphine as active ingredient | |
| EA201491747A1 (ru) | Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов | |
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| BRPI0913291A2 (pt) | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto | |
| EA201200086A1 (ru) | Замещенные 2-карбоксамиды циклоаминомочевин | |
| EA201170983A1 (ru) | Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии | |
| EA200900330A1 (ru) | Аналоги 2-феноксипиримидинона | |
| EA201590041A1 (ru) | Твердая форма холиновой соли вемурафениба | |
| EA201170672A1 (ru) | Соединения, пригодные для лечения целлюлита | |
| CL2011001026A1 (es) | Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato. | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: APREA THERAPEUTICS AB (SE) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/01/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25G | Requested change of headquarter approved |
Owner name: APREA THERAPEUTICS AB (SE) |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2558 DE 14/01/2020 QUANTO A PRIORIDADE UNIONISTA. |